giles introduces AI agent to accelerate healthcare and life science research

AI tool connects researchers to verified medical and life sciences global databases, enabling accurate extraction and summarisation of academic papers, journals, and articles

27-Oct-2025
AI-generated image

Symbolic image

giles AI, a company making advanced research tools accessible to all and simplifying how scientists work with data, has announced the commercial launch of giles, its AI specialised research agent designed to support healthcare, clinical, and medical research. By extracting, analysing, summarising, and referencing information from verified medical databases and private files, giles enables rapid literature review, accelerating research processes.

Using an LLM-agnostic approach, giles optimises research intelligence for scientific text comprehension, data accuracy validation, citation tracking, and domain-specific language understanding for medical, clinical, and academic settings. giles searches trusted sources of information, including private personal documents, to create easily digestible abstracts and comparisons of relevant data. In addition, it cites and verifies results, all completed within seconds. With an accuracy rate of up to 94% and available in over 40 languages, giles is applicable to all aspects of life science and healthcare research, including drug discovery and development, where the tool is enhancing workflows by providing access to real-time insights.

Following its initial development, refinement and subsequent commercialisation ofthe AI agent was supported through a strategic  partnership with Regulatory Scientific and Health Solutions (R-S-S), a leader in health economics and drug development, to connect researchers with open access medical databases. With ongoing support from Google UK, giles AI now has a series of high-profile collaborations with pharma companies, directly connecting researchers to medical databases.

Rishi Wadhera, CEO of giles AI, said: “giles is transforming the way we approach medical research literature review. Instead of spending hours researching, analysing, and organising data, users can simply ask our innovative AI agent, making healthcare research effortless. We are excited to share giles with both academics and researchers from across sector as we advance in our mission to make advanced AI research tools available to all, and look forward to seeing the scientific breakthroughs our technology facilitates.”

Other news from the department business & finance

Most read news

More news from our other portals

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.

Last viewed contents

Faster and more reliable crystal structure prediction of organic molecules

Faster and more reliable crystal structure prediction of organic molecules

Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease

Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease

Investigational monoclonal antibody to treat Ebola is safe in adults

Investigational monoclonal antibody to treat Ebola is safe in adults

NIH clinical trial of remdesivir to treat COVID-19 begins

NIH clinical trial of remdesivir to treat COVID-19 begins

APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease

CORAT Therapeutics obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101 - COR-101 is a human antibody that blocks virus infection by binding to the spike protein

CORAT Therapeutics obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101 - COR-101 is a human antibody that blocks virus infection by binding to the spike protein

New muscle therapy gets fast-track boost - Berlin start-up could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process

New muscle therapy gets fast-track boost - Berlin start-up could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process

SAS accelerates delivery of novel medicines using AI and analytics - Cooperation with AstraZeneca for more innovation in clinical research

SAS accelerates delivery of novel medicines using AI and analytics - Cooperation with AstraZeneca for more innovation in clinical research

Gentle protein purification at the touch of a button - i3 Membrane revolutionizes the separation of biological agents

Gentle protein purification at the touch of a button - i3 Membrane revolutionizes the separation of biological agents

Bio-based plastics for infusion bags - Frankfurt research team develops sustainable alternative to medical products made from crude oil in cooperation with bioplastics start-up BIOVOX

Bio-based plastics for infusion bags - Frankfurt research team develops sustainable alternative to medical products made from crude oil in cooperation with bioplastics start-up BIOVOX

Recipharm secures major additional grant to develop AI-enabled manufacturing technologies - Development of an AI-enabled simulator and process control platform, to speed up process development, cut costs and improve manufacturing efficiency

Recipharm secures major additional grant to develop AI-enabled manufacturing technologies - Development of an AI-enabled simulator and process control platform, to speed up process development, cut costs and improve manufacturing efficiency

Merck Partners with Promega Corporation

Merck Partners with Promega Corporation